Aleniglipron vs Orforglipron: Oral GLP-1 Pills Compared (2026)

Introduction#

Aleniglipron (GPCR0803, Structure Therapeutics) and orforglipron (Eli Lilly) are both oral non-peptide small molecule GLP-1 receptor agonists, representing the future of injection-free obesity treatment. This is arguably the most direct comparison in the GLP-1 pipeline: two small molecules targeting the same receptor, both taken as once-daily oral tablets without fasting restrictions, competing for the same patient population.

While orforglipron is further ahead in development with completed Phase 3 trials and FDA filing, aleniglipron's Phase 2b data suggest potentially competitive or even superior weight loss, particularly at higher doses.

Mechanism of Action Comparison#

Aleniglipron#

Aleniglipron is a non-peptide small molecule that selectively activates the GLP-1 receptor through a binding site distinct from the orthosteric peptide binding site. It suppresses appetite, delays gastric emptying, and enhances glucose-dependent insulin secretion. The molecule is taken as a once-daily oral tablet without the absorption enhancers or fasting requirements needed by peptide-based oral formulations.

Orforglipron#

Orforglipron is also a non-peptide small molecule GLP-1 receptor agonist. It selectively activates GLP-1 receptors, providing appetite suppression, delayed gastric emptying, and improved glucose homeostasis. Its oral bioavailability without absorption enhancers or fasting requirements is its key pharmaceutical advantage over oral semaglutide.

Two Molecules, Same Target#

Weight Loss Data#

*PA = placebo-adjusted

Cross-trial caveat: Aleniglipron's data is Phase 2b (smaller, shorter) while orforglipron has Phase 3 data (larger, longer). Placebo-adjusted weight loss (aleniglipron) and mean weight loss (orforglipron) are not directly comparable metrics. Phase 2 efficacy often diminishes in Phase 3.

Safety Comparison#

Key Differences Summary#

• Weight loss: Aleniglipron 11.3-15.3% PA (Phase 2b, 36 wk) vs orforglipron 12.4% mean (Phase 3, 72 wk)
• Development stage: Orforglipron has filed for FDA; aleniglipron is planning Phase 3
• GI tolerability: Aleniglipron has higher nausea rates (65% vs lower for orforglipron)
• Dose exploration: Aleniglipron explored higher doses (240 mg) with greater efficacy
• Maintenance data: Orforglipron has ATTAIN-MAINTAIN validation; aleniglipron does not
• T2D data: Orforglipron has ACHIEVE-3 head-to-head vs oral semaglutide
• Company backing: Eli Lilly (orforglipron) vs Structure Therapeutics (aleniglipron)

Conclusion#

The oral GLP-1 small molecule space is developing into a two-horse race between aleniglipron and orforglipron. Orforglipron has the clear lead in development, with completed Phase 3 trials, FDA filing, ATTAIN-MAINTAIN maintenance data, and the resources of Eli Lilly. Aleniglipron's Phase 2b results are intriguing, particularly the 15.3% placebo-adjusted weight loss at the exploratory 240 mg dose, which if confirmed in Phase 3 could be class-leading for oral agents. The GI tolerability challenge (65% nausea) will need to be addressed through optimized dose escalation. Both agents validate the oral small molecule GLP-1 approach as a viable alternative to injections, and competition between them should ultimately benefit patients.

Detailed Category Analysis#

Mechanism of Action#

Aleniglipron: Oral non-peptide small molecule GLP-1 receptor agonist. Activates GLP-1 receptors via a distinct binding site from peptide agonists. Once-daily oral dosing without fasting restrictions. Developed by Structure Therapeutics.

Orforglipron: Oral non-peptide small molecule GLP-1 receptor agonist. Activates GLP-1 receptors only, via a single mechanism. Once-daily oral tablet without fasting restrictions. Developed by Eli Lilly.

Advantage: Neither (tie)

Weight Loss Efficacy#

Aleniglipron: ACCESS Phase 2b showed 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks. Exploratory ACCESS II showed up to 15.3% placebo-adjusted at 240 mg at 36 weeks. 86% achieved 5% or more loss at 120 mg.

Orforglipron: ATTAIN-1 Phase 3 demonstrated 12.4% mean weight loss at 36 mg over 72 weeks. 36.0% achieved 15% or more loss. Meaningful but lower than injectable dual agonists.

Advantage: Aleniglipron

Development Stage#

Aleniglipron: Phase 2b ACCESS program completed. Phase 3 planned for mid-2026 following FDA discussions. Not filed for approval. Structure Therapeutics is a smaller biotech company.

Orforglipron: Phase 3 ATTAIN program completed. FDA submission filed. ATTAIN-MAINTAIN validated weight maintenance after switching from injectable. Backed by Eli Lilly's resources.

Advantage: Orforglipron

Safety and Tolerability#

Aleniglipron: Nausea in 65% at therapeutic doses. Vomiting in 32%. Discontinuation due to AEs was 11%. Tolerability improved with slower dose escalation starting at 2.5 mg. Weight loss persisted through 44 weeks.

Orforglipron: GI side effects most common (nausea, vomiting, diarrhea). Discontinuation due to AEs was 8.7-9.7% in ATTAIN trials. No injection site reactions. Larger safety database from Phase 3.

Advantage: Orforglipron

Dosing Convenience#

Aleniglipron: Once-daily oral tablet. No fasting restrictions required. Dose range explored from 2.5-240 mg. Optimal dose to be confirmed in Phase 3.

Orforglipron: Once-daily oral tablet. No fasting restrictions required. Three dose levels (12, 24, 36 mg) established from Phase 3. Can be taken with food and other medications.

Advantage: Neither (tie)

Summary and Verdict#

Aleniglipron and orforglipron are the two leading oral non-peptide small molecule GLP-1 agonists, competing directly for the same market. Aleniglipron's ACCESS Phase 2b data is numerically impressive (11.3% placebo-adjusted at 120 mg in 36 weeks, and up to 15.3% at 240 mg), suggesting it may match or exceed orforglipron's ATTAIN-1 results (12.4% mean at 72 weeks). However, orforglipron is further ahead in development with completed Phase 3, filed FDA submission, and the backing of Eli Lilly. The higher GI event rates with aleniglipron (65% nausea) versus orforglipron's profile are a concern, though dose optimization may improve tolerability. The oral GLP-1 space is poised for intense competition once both agents reach the market.

Best For Recommendations#

Earliest Available Oral GLP-1#

Recommendation: Orforglipron

Reason: Orforglipron has completed Phase 3 trials and filed for FDA approval, positioning it for earlier potential market entry. Aleniglipron is still planning its Phase 3 program.

Maximum Oral Weight Loss (Future)#

Recommendation: Aleniglipron

Reason: The exploratory 240 mg dose achieved up to 15.3% placebo-adjusted weight loss at 36 weeks, which if confirmed in Phase 3 could exceed orforglipron's 12.4%. The weight loss trajectory had not plateaued.

Weight Maintenance After Injectable#

Recommendation: Orforglipron

Reason: ATTAIN-MAINTAIN demonstrated that patients switching from injectable tirzepatide or semaglutide to orforglipron maintained their weight loss, validating oral step-down therapy. Aleniglipron has no maintenance data.

Type 2 Diabetes#

Recommendation: Orforglipron

Reason: ACHIEVE-3 showed orforglipron 36 mg was superior to oral semaglutide 14 mg for HbA1c reduction in a head-to-head Phase 3 trial. Aleniglipron T2D data is limited to early-phase studies.

Smaller Biotech Innovation#

Recommendation: Aleniglipron

Reason: Structure Therapeutics' distinct chemical scaffold and higher-dose exploration (240 mg) suggest a different optimization path. For those interested in next-generation oral GLP-1 chemistry, aleniglipron represents an alternative approach.

Further Reading#

• Aleniglipron Overview and Research Guide
• Aleniglipron Side Effects
• Aleniglipron Dosing Protocols
• Orforglipron Overview and Research Guide
• Orforglipron Side Effects
• Orforglipron Dosing Protocols